RO-634 half-life as compared to published data on Aflibercept, Faricimab, Ranibizumab, and Bevacizumab
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2022)